Business Description
Mesoblast is an Australian biotech company founded in 2004 that develops cell-based therapies to treat serious inflammatory and degenerative conditions across multiple countries. Its work centers on a specialized cell technology used to create treatments for conditions such as graft versus host disease, heart failure, inflammatory bowel disease, and chronic back pain. The company has formed partnerships with pharmaceutical firms including Tasly, JCR Pharmaceuticals, and Grünenthal to bring several of these therapies to patients around the world.
